Global Antisense and RNAi Therapeutic Market Size, Share, Growth, Trends and Forecasts, 2015 to 2022: Grand View Research

Global antisense & RNAi therapeutic market is expected to witness a lucrative growth rate during the forecast period owing to rising prevalence of infectious diseases, and coronary heart disorders which lead to cardiovascular diseases. Incorporation of technologically advanced RNA based technologies such as RNA antisense; RNA nanobiotechnologies, RNA interference, and SMaRT technology are also expected to drive market demand. Furthermore, growing needs for high throughput therapeutic tools for treatment of neurometabolic disorders such as amyotrophic lateral sclerosis, Huntington’s disease and Alzheimer’s disease, and rising awareness regarding tissue specificity for drug delivery about RNA based drugs are factors expected to fuel the growth for gene synthesizing mechanisms & cellular gene silencing. However, huge investment requirement in drug delivery & research and high treatment success rates are some factors that are expected to boost market growth.

Request to Sample of This Report @

Increasing awareness towards the use of aptamers and ribozymes for suppression of target genes, and there selective expression in order to treat diseases at a genomic level prior to protein expression is also expected to promote the market growth. Increasing usage of RNAi technology based therapeutics for infectious diseases such as HIV, viral hepatitis and cancer in order to overcome the adverse effects observed by consumption of generic drugs and inhibit the metabolic growth of causative micro-organism are expected to drive demand for antisense & RNAi therapeutic market through to 2022. Furthermore, approval of different novel drugs for the treatment of cholesterol associated disorders and ocular diseases are anticipated to have a positive impact on the growth of this market in the coming seven years.

The geographical analysis of antisense & RNAi therapeutic market divides it into Europe, North America, Asia-Pacific, Latin America and MEA. North America held the largest share in market revenue in 2014 as a consequence of rise in incidence of cardiovascular, genetic and neurometabolic disorders. Other factors contributing towards large market share of the region include rise in number of R&D institutes and laboratories involved in development of bioinformatics based research for disease prognosis. However, Asia Pacific region with emerging economies such as India and China is expected to grow at a significantly faster rate in the RNAi and antisense therapeutic market. Factors attributing this anticipated growth of this region include presence of unmet market demand, and increased used of miRNA as a disease marker for oncology diseases. Furthermore, presence of many antisense and siRNA molecules in the pipeline for drug development under clinical trials for regulatory approval is expected to fuel the market growth during the forecast period. Key participants in the market include Sanofi, Allergan, Benitec Biopharma, Biogen, Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb, Acuitas Therapeutics, Glaxosmithkline, Isis Pharmaceuticals, Dicerna Pharmaceuticals, Antisense Therapeutics, Dainippon Sumitomo Pharma, Roche Holding AG and Tekmira Pharmaceuticals. Competitive strategies adopted by the market players include collaborations for development and commercialization of antisense and RNAi drugs in the pharmaceutical and biotechnological market.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For More Information, Visit Grand View Research


Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519


Blog Site: